Moreover, FMT ameliorated the systemic inflammation in CKD and AKI recipients, since a reduction of many pro-inflammatory mediators (e.g., IFN-γ, IL-6, TNF-α, and IL-1β) was observed after the treatment [27,135,145,146]. Here, IL1B is linked to chronic kidney disease.